| 400.71 9.92 (2.54%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 510.34 | 1-year : | 596.08 |
| Resists | First : | 436.94 | Second : | 510.34 |
| Pivot price | 403.02  |
|||
| Supports | First : | 365.07 |
Second : | 320.64 |
| MAs | MA(5) : | 402.67 |
MA(20) : | 390.95 |
| MA(100) : | 294.35 |
MA(250) : | 245.16 |
|
| MACD | MACD : | 18.2 |
Signal : | 21.6 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 56.9 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 436.94 | Low : | 169.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NTRA ] has closed above bottom band by 45.6%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 407.25 - 409.71 | 409.71 - 412.07 |
| Low: | 386.11 - 388.95 | 388.95 - 391.68 |
| Close: | 396.3 - 400.54 | 400.54 - 404.6 |
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Fri, 09 Oct 2026
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Fri, 09 Oct 2026
Why Natera (NTRA) Stock Is Up Today - Yahoo! Finance Canada
Fri, 09 Oct 2026
Natera receives FDA breakthrough designation for multi-cancer blood test - Mugglehead Investment Magazine
Fri, 09 Oct 2026
A blood test for multiple cancers gets FDA breakthrough designation - Stock Titan
Thu, 08 Oct 2026
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Singapore
Wed, 07 Oct 2026
Natera: Priced To Perfection Amidst Rising Competitive Threats (NASDAQ:NTRA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 144 (M) |
| Held by Insiders | 1.3994e+008 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 4,960 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2442e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7.2 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | -8.1 % |
| Qtrly Rev. Growth | 2.71e+009 % |
| Gross Profit (p.s.) | 24.64 |
| Sales Per Share | -8.2 |
| EBITDA (p.s.) | 1.15686e+009 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 228 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 679.1 |
| Price to Book value | 0 |
| Price to Sales | -48.9 |
| Price to Cash Flow | 48.35 |
| Dividend | 0 |
| Forward Dividend | 4.3e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|